Sector News

Boston Scientific Outlines Growth And Expansion Strategy

May 4, 2015
Life sciences
(RTTNews.com) – Boston Scientific Corporation announced the company is targeting at- or above-market operational revenue growth, and consistent double-digit adjusted EPS growth (excluding the negative impact of foreign currency) through ongoing operating margin improvement initiatives, and a differentiated five-year growth strategy aims for 25 percent adjusted operating margins by 2017.
 
The company said it continues to increase penetration into emerging markets, which represented 10 percent of sales in 2014 on a reported basis, up from 8 percent in 2013. The company plans to move emerging market mix to 15 percent of sales in 2017 on a constant currency basis.
 
The company said a strategic alliance with Frankenman Medical Equipment is expected to support continued growth, development and manufacturing capabilities in China, and further expand the company’s global footprint.
 
“We continue to broaden our geographic reach and diversify our portfolio into markets with compelling growth opportunities. We are entering segments within each of our markets that are projected to grow faster than the overall market over the next five years, and we expect to continue to diversify our portfolio away from 60 percent in slower growth markets in 2012 to 40 percent by 2019,” said Dan Brennan, executive vice president and chief financial officer.
 

comments closed

Related News

April 14, 2024

Bayer taps new North America marketing chief for consumer health division

Life sciences

Avivi joins Bayer fresh off a yearlong stint as chief marketing officer of Advance Auto Parts, which followed about three years spent as marketing chief of another auto parts company, Tenneco. Rounding out her nearly 30-year career in marketing are leadership roles at consumer goods giants Kimberly-Clark and Procter & Gamble.

April 14, 2024

Air Liquide acquires healthcare businesses in Belgium and the Netherlands

Life sciences

Air Liquide S.A. (Paris) is continuing its development with the acquisition of Homecare activities in Belgium and the Netherlands. The two entities acquired in Belgium and the Netherlands support 10,000 patients living with respiratory insufficiency, sleep apnea syndrome or requiring infusion or nutrition treatments.

April 14, 2024

Vertex to acquire Alpine Immune Sciences for $4.9 billion

Life sciences

US-based Vertex Pharmaceuticals has agreed to pay approximately $4.9 billion in cash to acquire Alpine Immune Sciences, a compatriot biotechnology company focused on discovering and developing innovative, protein-based immunotherapies.

How can we help you?

We're easy to reach